Biom'Up provides regulatory update regarding HEMOBLASTâ„¢ Bellows

27-10-2017 08:00

Saint-Priest, France, October 27, 2017 – Biom’Up, specialist of surgical hemostasis, today provides a regulatory update regarding the United States Food and Drug Administration’s (FDA) review of the company’s Premarket Approval (PMA) application for its HEMOBLASTTM Bellows.

PDF-file 590.8kb

Dutch version - French version - German version